Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
| Autor: | Mysler, E, Tanaka, Y, Kavanaugh, A, Aletaha, D, Taylor, PC, Song, I-H, Shaw, T, Song, Y, DeMasi, R, Ali, M, Fleischmann, R |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Rheumatology. 62:1804-1813 |
| ISSN: | 1462-0332 1462-0324 |
| Popis: | Objectives Evaluate the importance of treatment sequencing in SELECT-COMPARE, assessing potential differences between starting upadacitinib or adalimumab therapy following inadequate MTX response. Methods Patients from SELECT-COMPARE were randomized to upadacitinib 15 mg once daily, placebo or adalimumab 40 mg. Per protocol, patients with Results This post hoc analysis included 651 patients initially randomized to upadacitinib (of whom 252 switched to adalimumab) and 327 patients initially randomized to adalimumab (of whom 159 switched to upadacitinib). At week 48, patients randomized to either therapy demonstrated similar achievement of most treatment endpoints. Greater improvements in the total time spent in a lower disease state were observed for initial upadacitinib vs initial adalimumab therapy across most clinical and patient-reported outcomes through 48 weeks, and the median time to DAS28(CRP) Conclusion Following a modified treat-to-target strategy, rates of CDAI remission/LDA and DAS28(CRP) Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT02629159 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|